Fibrodysplasia Ossificans Progressiva Pipeline and Clinical Trials Assessment (2023) | Companies- Ipsen, Blueprint Medicines, Regeneron Pharmaceuticals, Daiichi Sankyo Inc, AstraZeneca, Incyte Corporation, and others

DelveInsight's, "Fibrodysplasia Ossificans Progressiva Pipeline Insight 2023" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Fibrodysplasia Ossificans Progressiva pipeline landscape. It covers the Fibrodysplasia Ossificans Progressiva pipeline drug profiles, including Fibrodysplasia Ossificans Progressiva clinical trials and nonclinical stage products. It also covers the Fibrodysplasia Ossificans Progressiva therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The pipeline analysis report for emerging drugs in Fibrodysplasia Ossificans Progressiva offers a comprehensive and holistic perspective of the therapeutic landscape. It encompasses the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Fibrodysplasia Ossificans Progressiva pipeline covers multiple facets including business opportunities, challenges, potential partnerships, formidable competitors, and growth strategies. Each drug is described in detail, including its mechanism of action, clinical trial studies conducted for Fibrodysplasia Ossificans Progressiva, any obtained NDA approvals, and product development activities such as technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other pertinent information.

To explore more information on the latest breakthroughs in the Fibrodysplasia Ossificans Progressiva Pipeline treatment landscape of the report, click here @ Fibrodysplasia Ossificans Progressiva Pipeline Outlook- https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Fibrodysplasia Ossificans Progressiva Pipeline Report
• DelveInsight's Fibrodysplasia Ossificans Progressiva Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading Fibrodysplasia Ossificans Progressiva Companies are working in the market include Ipsen, Blueprint Medicines, Regeneron Pharmaceuticals, Daiichi Sankyo Inc, AstraZeneca, Incyte Corporation, and others.
• Promising Fibrodysplasia Ossificans Progressiva Pipeline Therapies in the various stages of development include Palovarotene, Garetosmab, REGN2477, INCB000928, IPN60130, and others
• Regeneron has been engaged in FOP research for over two decades and helped to provide fundamental insights in the biology and natural history of the disease. Regeneron scientists discovered that Activin A plays a key role in FOP by driving HO, the main pathology of FOP. Garetosmab is a VelocImmune-derived fully-human monoclonal antibody that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP. Garetosmab is currently being studied in adults with FOP. In 2017, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for garetosmab for the prevention of HO in patients with FOP. In the U.S. and European Union (EU), garetosmab has been granted Orphan Designation. Garetosmab is currently under clinical development, and its safety and efficacy have not been evaluated by any regulatory authority. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Fibrodysplasia Ossificans Progressiva.
• INCB000928 is a novel drug (to be taken by mouth) which inhibits ALK2 activity and prevents ossification in a laboratory mouse model of FOP. INCB000928 significantly reduces the production of hepcidin in human liver cells, primary hepatocytes and rodent models of anemia, and has shown efficacy in preventing injury-induced heterotopic ossification in a human FOP mouse model, offering a promising path to clinical proof-of-efficacy studies and potential benefits to patients with hepcidin-induced anemia and FOP.
• IPN60130 is an oral investigational drug designed to selectively target the mutant FOP receptor (ACVR1/ALK2), the underlying cause of FOP. FDA has granted Fast Track Designation to IPN60130 for the treatment of FOP. IPN 60130 is an oral selective ALK2 inhibitor. Formerly known as BLU-782, it was developed by Blueprint Medicines, which in 2019 entered a license agreement with Ipsen for the development and commercialization of the drug. Prior to that, the drug had been awarded orphan designation, rare pediatric disease designation, and fast track designation by the FDA. Pre-clinical data showed that IPN 60130 prevented heterotopic ossification caused by injury or surgery, reduced edema and restored healthy tissue response. Preliminary results of a Phase I clinical trial released in 2019 indicated that the drug was well-tolerated at all doses tested. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Fibrodysplasia Ossificans Progressiva.

Fibrodysplasia Ossificans Progressiva Overview
Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles. Specifically, this disorder causes the body's skeletal muscles and soft connective tissues to undergo a metamorphosis, essentially a transformation into bone, progressively locking joints in place and making movement difficult or impossible.

For further information, refer to the detailed Fibrodysplasia Ossificans Progressiva Unmet Needs, Fibrodysplasia Ossificans Progressiva Market Drivers, and Fibrodysplasia Ossificans Progressiva Market Barriers, click here for Fibrodysplasia Ossificans Progressiva Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Fibrodysplasia Ossificans Progressiva Emerging Drugs Profile
• REGN2477: Regeneron
• INCB000928: Incyte Corporation
• IPN60130: Ipsen

Fibrodysplasia Ossificans Progressiva Pipeline Therapeutics Assessment
There are approx. 10+ Fibrodysplasia Ossificans Progressiva companies which are developing the therapies for Fibrodysplasia ossificans progressiva. The Fibrodysplasia Ossificans Progressiva companies which have their Fibrodysplasia ossificans progressiva drug candidates in the most advanced stage, i.e. Phase III include, Regeneron.

Request a sample and discover the recent advances in Fibrodysplasia Ossificans Progressiva Ongoing Clinical Trial Analysis and Medications, click here @ Fibrodysplasia Ossificans Progressiva Treatment Landscape- https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Fibrodysplasia Ossificans Progressiva Pipeline Segmentation
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Fibrodysplasia Ossificans Progressiva Therapeutics Market include-
Ipsen, Blueprint Medicines, Regeneron Pharmaceuticals, Daiichi Sankyo Inc, AstraZeneca, Incyte Corporation, and others

Dive deep into rich insights for drugs for Fibrodysplasia Ossificans Progressiva Pipeline, click here @ Fibrodysplasia Ossificans Progressiva Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Fibrodysplasia Ossificans Progressiva Pipeline Report
• Coverage- Global
• Fibrodysplasia Ossificans Progressiva Companies- Ipsen, Blueprint Medicines, Regeneron Pharmaceuticals, Daiichi Sankyo Inc, AstraZeneca, Incyte Corporation, and others
• Fibrodysplasia Ossificans Progressiva Pipeline Therapies- Palovarotene, Garetosmab, REGN2477, INCB000928, IPN60130, and others.
• Fibrodysplasia Ossificans Progressiva Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Fibrodysplasia Ossificans Progressiva Mergers and acquisitions, Fibrodysplasia Ossificans Progressiva Licensing Activities @ Fibrodysplasia Ossificans Progressiva Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Fibrodysplasia Ossificans Progressiva Executive Summary
3. Fibrodysplasia ossificans progressiva: Overview
4. Fibrodysplasia Ossificans Progressiva Pipeline Therapeutics
5. Fibrodysplasia Ossificans Progressiva Therapeutic Assessment
6. Fibrodysplasia ossificans progressiva - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. REGN2477: Regeneron
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. INCB000928: Incyte Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DS 6016: Daiichi Sankyo
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Fibrodysplasia ossificans progressiva Key Companies
18. Fibrodysplasia ossificans progressiva Key Products
19. Fibrodysplasia ossificans progressiva- Unmet Needs
20. Fibrodysplasia ossificans progressiva- Market Drivers and Barriers
21. Fibrodysplasia ossificans progressiva- Future Perspectives and Conclusion
22. Fibrodysplasia ossificans progressiva Analyst Views
23. Fibrodysplasia ossificans progressiva Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.